

Sustainability of the HIV-AIDS Response: *Getting to 2030 & Beyond*

A National Academy of Medicine Workshop

NAS Building Lecture Room

September 18, 2024



Table of Contents

Agenda	3
Planning Committee Members	5
Speakers & Moderators	11
Statement of Discrimination, Harassment, and Bullying	24
Diversity, Equity, and Inclusion Statement and Guiding Principles	25

Agenda

Meeting Aims:

Explore how to re-energize the global HIV response to reach the 2030 goals as well as craft strategies to increase and sustain political commitment and highlight global accountability and domestic-donor financing.

- 8:30 – 9:00 AM **Registration and Optional Breakfast Available**
East Court
- 9:00 – 9:15 AM **Welcome and Introduction**
- Victor Dzau, National Academy of Medicine
 - Carlos del Rio, Emory University School of Medicine
- 9:15 – 9:25 AM **Reflections**
- Jim Yong Kim, Global Infrastructure Partners
- 9:25 – 9:55 AM **Opening Comments**
- John N. Nkengasong, U.S. Department of State
- 9:55 – 11:55 AM **Post-2030 Strategy: Achieving 2025 Goals & Optimizing Future Response**
Moderator: Carlos del Rio, Emory University School of Medicine
- Wafaa El-Sadr, ICAP at Columbia University
 - Eric Goosby, University of California San Francisco
 - Jennifer Kates, KFF
 - Yogan Pillay, Bill & Melinda Gates Foundation
 - Michel Sidibé, African Medicines Agency
- 11:55 – 12:30 PM **Break**
Lunch is available in the East Court
- 12:30 – 2:30 PM **Sustaining Political Commitment to Ending HIV as a Public Health Threat**
Moderator: Robert Redfield, University of Maryland
- Deborah Birx, Texas Tech University of Health Sciences
 - Chris Collins, Friends of the Global Fight
 - Austin Demby, Sierra Leone Ministry of Health and Sanitation
 - Jean William “Bill” Pape, Weill Cornell Center of Global Health & GHESKIO
 - Shepherd Smith, Children’s AIDS Fund International

2:30 - 2:50 PM

Break

Snacks are available in the East Court

2:50 - 4:50 PM

Global Accountability: Domestic and Donor Support

Moderator: Peter Piot, European Commission

- Winnie Byanyima, UNAIDS
- Mark Dybul, Georgetown University
- Tom Frieden, Resolve to Save Lives
- Muhammad Pate, Nigeria Ministry of Health and Social Welfare
- Peter Sands, Global Fund

4:50 - 5:00 PM

Closing Remarks

- Carlos del Rio, Emory University School of Medicine

5:00 PM

Adjourn

Planning Committee Members



Carlos del Rio, M.D. (Chair)

Carlos del Rio, MD is the Leon L. Haley, Jr Distinguished Professor of Medicine and Chair of the Department of Medicine at Emory University School of Medicine. He is also Professor of Global Health and Epidemiology at the Rollins School of Public Health. Dr. del Rio is co-Director of the Emory Center for AIDS Research and co-PI of the Emory Vaccine and Treatment Evaluation Unit. A native of Mexico where he attended medical school graduating with honors in 1983. He did his Medicine and Infectious Diseases training at Emory. In 1989 he returned to Mexico where he was Executive Director of the National AIDS Council. In 1996 Dr. del Rio returned to Emory where he is involved in patient care, teaching and research. He is the Immediate Past President of the Infectious Diseases Society of America and the chair of the PEPFAR Scientific Advisory Committee. del Rio was elected to the National Academy of Medicine in 2013 and elected as the Academy's International Secretary in 2020 and reelected in 2024.



Victor J. Dzau, M.D.

Victor Dzau is President of the US National Academy of Medicine (NAM), Vice-Chair of the US National Research Council, Chancellor Emeritus of Duke University, and past CEO of Duke Health System. Previously, he was Professor and Chairman of Medicine at both Harvard and Stanford Universities. Dr. Dzau is recognized globally for a long and highly decorated career as a scientist, administrator, and leader. His research laid the foundation for development of lifesaving drugs known as ACE inhibitors, used globally to treat high blood pressure and congestive heart failure.

Dzau brings a global perspective and activist orientation to the NAM. He designed and leads important initiatives including the Commission on a Global Health Risk Framework, Roadmap for Healthy Longevity, the International Human Gene Editing Initiative; Vital Directions

for Health and Health Care; Confronting the Opioid Crisis; and the Grand Challenge in Climate Change and Human Health.

A leader in global health, Dzaou serves on the Global Preparedness Monitoring Board, is a principal of the ACT Accelerator, was advisor to G20 High Level independent panel on Financing for Pandemic Preparedness and Response, co-chaired the G20 Scientific Panel on Global Health Security, and serves as an advisor to the G7 (Japan) Health Task Force. He co-leads the World Economic Forum Regional Vaccine Manufacturing Collaborative and is co-chair of the Science and Technology Expert Panel for the Independent Pandemic Preparedness Secretariat for the 100 Day Mission.

Among his many honors and recognitions are the Gustav Nylin Medal from the Swedish Royal College of Medicine, the Research Achievement Award from the American Heart Association, the Ellis Island Medal of Honor, the Poulzer Prize of the European Academy of Sciences and Arts, the Henry Freisen International Prize, and the Porter Prize of the University of Pittsburgh. He was made an Honorary Citizen of Singapore, the highest honor bestowed to a foreign individual. He has received 20 honorary doctorates.



John N. Nkengasong, M.D.

John N. Nkengasong is an Ambassador-at-Large and serves as the U.S. Department of State's U.S. Global AIDS Coordinator and Senior Bureau Official for Global Health Security and Diplomacy (GHSD). Ambassador Nkengasong oversees the Bureau of Global Health Security and Diplomacy; which serves as the Department's coordinating body for work on strengthening global health security to prevent, detect, and respond to infectious diseases, including HIV/AIDS; as well as elevates and integrates global health security as a core component of U.S. national security and foreign policy. GHSD is home to the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), which the Ambassador also oversees. PEPFAR is the largest commitment by any nation to address a single disease in history and has prevented millions of HIV infections, saved

more than 25 million lives, and has changed the course of the HIV/AIDS pandemic. Under his leadership, the program is laser focused on ending HIV/AIDS as a public health threat by 2030.



Deborah Birx, M.D.

Deborah L. Birx, M.D., spent her first career serving the United States, as an Army Colonel and later, running some of the most high-profile and influential programs at the U.S. Centers for Disease Control and Prevention and U.S. Department of State as a civil servant. Dr. Birx is known for successful increasing overall effectiveness of programs through granular data use and effective change management. Dr. Birx is a medical expert and leader whose long career has focused on clinical and basic immunology, infectious disease, pandemic preparedness, vaccine research, and global health. Dr. Birx served as the White House Coronavirus Response Coordinator using complex data set integration to drive decision-making and working closely with state officials across the country to provide state-specific advice and guidance. In her second career she is applying the lessons learned from 4 decades driving change management in the Federal government and using data to drive continuous program improvements to important private sector endeavors. Dr. Birx completed her first book entitled *Silent Invasion* published by HarperCollins 2022. She is a Bush Institute Senior Fellow and a Professor at Texas Tech University of Health Sciences and is dedicated to transforming healthcare access in rural America.



Mark Dybul, M.D.

The Honorable Mark Dybul, MD, is a Professor in the Department of Medicine at Georgetown University Medical Center where he serves as Chief Strategy Officer of the Center for Global Health Practice and Impact, Interim Chair of Purpose Africa, and CEO of Renovaro, Inc.

Mark has worked on HIV and public health for more than 25 years as a clinician, scientist, teacher, and administrator. He

was a principal architect of, and ultimately led, the US President's Emergency Plan for AIDS Relief (PEPFAR). Most recently, he served as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. After graduating from Georgetown Medical School in Washington D.C., Mark joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. His first supervisor was Dr. Drew Weissman, who recently received the Nobel Prize for his role in the mRNA COVID-vaccine. Mark was one of the founding architects in the formation of PEPFAR. After serving as Chief Medical officer, Assistant, Deputy and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. He also served as Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 to 2017. Mark has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards, and is a member of the National Academy of Medicine.



Anthony S. Fauci, M.D

Anthony S. Fauci, M.D., is currently Distinguished University Professor at Georgetown University School of Medicine, and McCourt School of Public Policy. He formerly served as director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health from 1984 to 2022. Dr. Fauci was a key advisor to seven Presidents on global HIV/AIDS issues, and on preparedness against emerging infectious disease threats. He also served as the Chief Medical Advisor to President Joe Biden. Dr. Fauci was one of the principal architects of the President's Emergency Plan for AIDS Relief (PEPFAR), which has helped save more than 25 million lives throughout the developing world. Dr. Fauci is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and many other professional societies. He has received numerous awards including the Presidential

Medal of Freedom, the National Medal of Science, and the Mary Woodard Lasker Award for Public Service.



Eric Goosby, M.D.

Eric Goosby, M.D., is an internationally recognized expert on infectious diseases, with a specialty in HIV/AIDS clinical care, research, and policy. During the Clinton Administration, Dr. Goosby was the founding director of the Ryan White CARE Act, the largest federally funded HIV/AIDS program in the U.S. He went on to become the interim director of the White House's Office of National AIDS Policy. In the Obama Administration, Dr. Goosby was appointed Ambassador-at-Large and implemented the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), which significantly expanded under his tenure life-saving HIV treatment to millions in Sub Saharan Africa, SE Asia, and Eastern Europe. After serving as the U.S. Global AIDS Coordinator, he was appointed by the UN Secretary-General as the Special Envoy on Tuberculosis in 2015 where he focused on the first-ever UN High-Level Meeting on TB in 2019. Most recently, he served as a member of the Biden-Harris Transition COVID-19 Advisory Board. He is currently a Professor of Medicine at the UCSF School of Medicine and leading the Center for Global Health Delivery, Diplomacy and Economics, Institute for Global Health Sciences. He is a member of the Western States Scientific Safety Review Workgroup, and serves on the San Francisco Dept. of Public Health, Policy Group for the COVID-19 Response.




Peter Piot, M.D., Ph.D.

Peter Piot MD PhD is a Professor of Global Health and former Director of the London School of Hygiene & Tropical Medicine. He is Special Advisor to EC President von der Leyen on European and Global Health Security, EU Chief Scientific Advisor Epidemics, a Senior Advisor at the Gates Foundation, and visiting professor at the Rega Institute, KU Leuven, the University of Antwerp, and the National University of Singapore. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations. He co-discovered the Ebola virus in 1976,

and led research on HIV, women's health and infectious diseases. He has an MD from University of Ghent and a PhD from the University of Antwerp, and worked at the Institute of Tropical Medicine, Antwerp; the University of Washington, Seattle; the University of Nairobi; Imperial College London; the College de France, and the Gates Foundation. He is a member of the Belgian, American, British, and French National Academies of Medicine, and the German Academy of Sciences Leopoldina. He is Chair of the Strategic Committee of the Pasteur Network, Vice-Chair of GHIT Fund, Tokyo, and was a founding Board Member of CEPI, and of the Global Fund to fight AIDS, TB, Malaria. He was made a Baron in his native Belgium, and received a UK Knighthood, and the Grand Cordon of the Rising Sun, Japan. His awards include the Canada Gairdner Global Health Award, Robert Koch Gold Medal, Prince Mahidol Award, Hideyo Noguchi Africa Prize, Nelson Mandela Award for Health and Human Rights, WHO Life Achievement Award, and was a 2014 TIME Person of the Year. He has published over 650 scientific articles and 17 books, including his memoir, No Time to Lose, available in 5 languages. He lives in Belgium.

Speakers & Moderators



Jim Yong Kim M.D., Ph.D.

Jim Yong Kim M.D., Ph.D., is Vice Chairman and Partner at Global Infrastructure Partners.

From July 2012 to February 2019, Kim served as the 12th President of the World Bank Group. Soon after he assumed that position, the organization established two goals to guide its work: to end extreme poverty by 2030; and to boost shared prosperity, focusing on the bottom 40 percent of the population in developing countries.

During Kim's tenure, the World Bank achieved successive, record replenishments of the institution's fund for the poorest countries and secured an historic capital increase which more than doubled its lending capacity. The WBG also launched facilities to address infrastructure needs, prevent pandemics, and help the millions of people affected by climate shocks, conflict, and violence.

A physician and anthropologist, Kim's career has revolved around health, education, and improving the lives of the poor. Before joining the WBG, he served as the President of Dartmouth College and held professorships at Harvard Medical School and the Harvard School of Public Health. Kim also served as Director of the World Health Organization's HIV/AIDS department and led its "3 by 5" initiative, the first-ever global goal for AIDS treatment, which greatly expanded access to antiretroviral medication in developing countries. In 1987, Kim co-founded Partners In Health, a non-profit medical organization.

Kim received a MacArthur "Genius" Fellowship, was recognized as one of America's "25 Best Leaders" by U.S. News & World Report and was named one of TIME magazine's "100 Most Influential People in the World."



Wafaa El-Sadr, M.D., M.P.H., M.P.A.

Wafaa El-Sadr is Executive Vice President for Columbia Global, University Professor of Epidemiology and Medicine, Director of ICAP at Columbia University and the Mathilde Krim-amfAR Professor of Global Health at the Columbia Mailman School of Public Health. As the EVP for Columbia Global, she oversees this University-wide initiative which aims at advancing global research, programs and training. She founded and directs ICAP, a global health center at the Columbia Mailman School of Public Health, working in more than 40 countries around the world, which integrates research, education and training, program design, implementation, scale-up and evaluation. ICAP's work is centered on health systems strengthening through partnership with governments, non-governmental organizations, civil society group, academic institutions and communities. Dr. El-Sadr received her medical degree from Cairo University in Egypt, a master's degree in public health (Epidemiology) from Columbia Mailman School of Public Health and a master's degree in public administration from the Harvard University Kennedy School of Government. She was named a McArthur fellow in 2008, a member of the National Academy of Medicine in 2009, a fellow of the African Academy of Sciences in 2018 and a member of the Council for Foreign Relations in 2021.



Jennifer Kates, M.P.A., M.A.

Dr. Jennifer Kates is senior vice president and director of the Global Health & HIV Policy Program at KFF, where she oversees policy analysis and research focused on the U.S. government's role in global health and on the global and domestic HIV epidemics. She has also helped to lead KFF's work on the COVID-19 pandemic. Widely regarded as an expert in the field, she regularly publishes and presents on global health and HIV policy issues and is particularly known for her work analyzing donor government investments in global health; assessing and mapping the U.S. government's global health architecture, programs, and funding; and tracking and analyzing major U.S. HIV programs and financing, and key trends in the HIV epidemic, an area she has been working in for close to 30 years.



Yogan Pillay, Ph.D.

Dr. Yogan Pillay works as the director for HIV and TB delivery at the Bill & Melinda Gates Foundation. He served as the country director of the Clinton Health Access Initiative in South Africa and senior director for universal health coverage (June 2020 to April 2023). He is the former Deputy Director-General of Health in the Department of Health, South Africa responsible for health programs (2008-2020). He obtained a Ph.D. from the Johns Hopkins Bloomberg School of Public Health and has co-written two textbooks on global health, co-edited a book on mental health and one on the South African health system. He has authored and co-authored more than 100 peer reviewed journal articles. He serves as an academic editor for Plos One and reviewer of several journals and has been a member of a number of regional and global health initiatives. In 2018 he was awarded the Karel Styblo Medallion and presented with a certification of appreciation for leadership in the global fight against tuberculosis by KNCV. In 2020 the Rotary International Board named him a Paul Harris Fellow in recognition of his work on child health. He is an affiliate of the Center for Innovation in Global Health, Georgetown University. In 2021 he was awarded an honorary doctorate by the University of Cape Town and in the same year appointed extraordinary professor in the Division of Health Systems and Public Health, Department of Global Health, Stellenbosch University.



Michel Hamala Sidibé

Michel Hamala Sidibé was appointed as the African Union (AU) Special Envoy for the African Medicines Agency in April 2021 by H.E. Moussa Faki Mahamat, Chairperson of the African Union Commission. Entrusted with the critical mission of accelerating the ratification of the AMA Treaty, Sidibé tirelessly mobilized AU Member States and key stakeholders, leading to the Treaty's successful entry into force on 5 November 2021. A former Minister of Health and Social Affairs for Mali (2019-2020), Sidibé has been a staunch

advocate for people-centered health and development for over 40 years. He served as the Executive Director of UNAIDS, with the rank of Under-Secretary-General of the United Nations (2009-2019). His tenure at UNAIDS was marked by a transformative vision of zero new HIV infections, zero discrimination, and zero AIDS-related deaths, inspiring millions within the global health movement. Under his leadership, over 25 million people gained access to life-saving HIV treatment, and global resources for the fight against AIDS grew from \$9 billion to \$22 billion. Sidibé is also a relentless champion of African-owned solutions and has been a vocal advocate for the local production of medicines and essential health commodities. He has played a significant role in advancing access to quality and safe medicines and vaccines while combating global inequities. In recognition of his contributions, he was appointed as a board member of the Global Commission on Drug Policy in 2021. In 2019, AU Member States expressed their profound gratitude to Sidibé for his invaluable contributions to the AU's objectives, including Agenda 2063. An economist by training, Michel Hamala Sidibé has received numerous African and global awards, including honorary doctorates from some of the world's leading universities. In 2017, he was awarded the Emory President's Medal in recognition of his work as a "passionate champion for health and humanity."



Robert R. Redfield, M.D.

Dr. Robert R. Redfield engaged in clinical research and clinical care of chronic human viral infections and infectious diseases, especially HIV and chronic viral diseases, for more than 35 years. Dr. Redfield was appointed as the 18th Director of the Centers for Disease Control and Prevention to oversee the agency's domestic and global public health efforts including activities of all of the agency's centers. Additionally, at the same time he was appointed as Administrator of the Agency for Toxic Substances and Registry.

Prior to CDC he served as the founding director of the Department of Retroviral Research within the Military's HIV Research Program, and retired after 20 years of service in the US Army Medical Corp, when he co-founded the University of

Maryland's Institute of Human Virology with Dr. William Blattner and Dr. Robert C. Gallo. He served as Professor of Medicine, Professor of Microbiology and Immunology, and as the IHV Associate Director and Director of the Division of Clinical Care and Research at the Institute of Human Virology, as well as providing leadership as the Chief of Infectious Diseases and Vice Chair of Medicine at the University of Maryland, School of Medicine. In 2021, Dr. Redfield has been appointed by Governor Hogan to serve as senior public health advisor for the State of Maryland until 2023. Dr. Redfield also serves as a visiting senior fellow for biosecurity and public health policy at the Heritage Foundation. In addition, he is the president of R3 Enterprises and Consulting which provides strategic advice to health care, biotech, public health companies.

Dr. Redfield made several important early contributions to our understanding of HIV, to include the demonstration of the importance of heterosexual transmission and the development of the Walter Reed staging system for HIV infection, and the demonstration of active HIV replication in all stages of infection. His present research interest is focused on targeting host cell pathways as novel strategies for the treatment and prevention of HIV infection and chronic viral pathogens. He has served as a member of the US President's Advisory Council on HIV/AIDS from 2005-2009, and was appointed as Chair of the International Subcommittee from 2006-2009. He is past member of the Office of AIDS Research Advisory Council at the National Institutes of Health, the Fogarty International Center Advisory Board at the National Institutes of Health, and the Advisory Anti-Infective Agent Committee of the Food and Drug Administration. He served as member of the Board for Operation Warp Speed responsible for bringing Covid-19 vaccines to public health practice in record time and he served as a member the White House Coronavirus Task Force.

While at the University of Maryland, Dr. Redfield led extensive USG funded global HIV care and treatment programs, and vibrant global post-graduate medical education programs, which were active in 7 African countries and 2 Caribbean country, serving more than 700,000 people living with HIV. His commitment to global health continues now serving as

president of PDTi, a new global vaccine and antiviral distribution company.



Chris Collins, M.P.P.

Chris joined Friends in 2016 and serves as its President & CEO. He leads the organization's efforts to engage U.S. decision makers on the lifesaving work of the Global Fund to Fight AIDS, Tuberculosis and Malaria and the importance of expanding global health investment. Chris has been active in HIV policy and advocacy for over 30 years. At Friends, Chris has played a central role in major global health financing wins. He has also written widely on the connection between disease-focused programs and broader health goals. Previously, as Chief of the Community Mobilization Division at UNAIDS, Chris helped make the case for investment in civil society as an essential part of the AIDS response. As Vice President and Director of Public Policy at amfAR, Chris defended global AIDS research and program funding and worked to advance domestic HIV policy and global key populations programming. Chris authored the monograph that inspired the effort to create the first comprehensive US National HIV/AIDS Strategy, then coordinated the successful advocacy push to establish the Strategy, leading to important policy reforms. He helped develop and managed the International Treatment Preparedness Coalition (ITPC) Missing the Target series of reports on global HIV treatment scale up which received international attention. Chris co-founded and served as Executive Director at AVAC, an internationally recognized HIV research and prevention advocacy group. As appropriations staff to Rep. Nancy Pelosi (D-CA) in the late 1990s, Chris led her HIV work and designed the first legislation to provide incentives for development and delivery of vaccines against HIV, tuberculosis and malaria, a bill that helped advance the global dialogue on tackling major infectious diseases. He holds a master's degree in public policy from the Kennedy School of Government at Harvard University.



Austin Demby, M.D.

Dr. Austin Demby Minister of Health and Sanitation Government of Sierra Leone Dr. Austin Demby serves as the Minister of Health and Sanitation for the Government of Sierra Leone. Before his current appointment, Dr. Demby was the Acting Director of the Office of Global Health at the U.S. Health Resources and Services Administration (HRSA). Dr. Demby's public health career began in 1980 as a research scientist at the Centers for Disease Control and Prevention (CDC). From 1987 to 1989, he was the Country Director of the CDC field station in Sierra Leone, where he focused on studying Lassa fever and other viral hemorrhagic fevers. His research appointments include notable institutions such as: Special Pathogens Branch, Virus Reference Laboratory, Central Public Health Laboratory Services, Colindale, United Kingdom (1990-1993), Division of Pathology, Center for Applied Microbiology and Research, Porton Down, United Kingdom (1993-1994), Special Pathogens Branch, DVRD, NCID (1994-1997); and, Diagnostic Mycobacteriology, TMB, DASTLR, NCID (1998-1999). Transitioning from biological research, Dr. Demby was a founding member of CDC's Global AIDS Program (GAP). Between 1999 and 2006, he led teams that established GAP program offices in Ethiopia, Rwanda, Tanzania, Zambia, and the Democratic Republic of Congo. From 2006 to 2011, he directed the CDC Malawi program, overseeing HIV/AIDS prevention, treatment, and care activities, while facilitating major programs funded by HRSA and NIH in Malawi. From 2011 to 2016, Dr. Demby served as the Director and Deputy Principal for the President's Emergency Plan for AIDS Relief (PEPFAR) at the U.S. Department of Health and Human Services. He managed a \$2 billion global HIV/AIDS portfolio implemented by five U.S. government health agencies.

During the 2014-2015 Ebola outbreak in West Africa, Dr. Demby played a critical leadership role in the U.S. Government's response. He was the first U.S. official to conduct a rapid technical assessment in Sierra Leone and alert the global community, deploying to the region five times in various capacities. Dr. Demby holds a Doctorate in Clinical Microbiology from the University of London, a Master's degree in Public Health with a focus on Epidemiology and Biostatistics from the University of

Michigan, and a Bachelor of Science degree with honors from Fourah Bay College, University of Sierra Leone.



Jean William Pape, M.D.


Dr. Jean "Bill" Pape is the founder and director of Les Centres GHESKIO (Haitian Study Group on Kaposi Sarcoma and Opportunistic Infections) in Port-au-Prince, Haiti, and the Howard and Carol Holtzmann Professor of Clinical Medicine at Weill Cornell Medical College in New York.

Dr. Pape is a visionary leader whose seminal work has had a major impact on healthcare delivery in his native country of Haiti and around the world. Despite incredible challenges, he has persevered to save countless lives in Haiti while improving many more globally. His story and that of GHESKIO, the organization he founded, exemplify resilience, innovation, and entrepreneurial leadership in one of the poorest countries in the world.

Bill Pape graduated from Columbia (BS, 1971) and Cornell (MD, 1975) universities. In 1980, after completing his training in infectious diseases, he set-up the Cornell program in Haiti where he developed an effective care model for infants with diarrhea. Expansion of the model nationwide resulted in a 50% decrease in national infantile mortality. Dr Pape is also credited with the recognition and 1st comprehensive description of AIDS in the developing world. In 1982, he established GHESKIO as one of the 1st AIDS centers in the world.

With cardiovascular disease (CVD) now surpassing AIDS and TB as the leading cause of mortality in Haiti, he responded by opening a CVD center in 2018, introducing innovative services and treatments to address this critical issue. Four decades later, GHESKIO remains one of the largest AIDS and TB treatment, training, and research centers in the Americas, providing free care to more than 300,000 patients with HIV, STIs, TB, diarrheal, and cardiovascular diseases annually. In 2020, Dr. Pape was selected to co-lead Haiti's national response to the COVID-19 pandemic.

Dr Pape received many awards including the Légion d'Honneur (France, 2002), member of the National Academy of Medicine (2003); Carlos Slim, Institut de France's Christophe Mérieux, Gates Global Health, Clinton Global Citizen (2010); Haiti's highest honor (2014); member of the WHO Science Council (2021), and of the American Academy of Arts and Sciences (2022).



Shepherd Smith

For over 38 years Shepherd Smith has been a leader in HIV/AIDS, youth development, maternal & child health, WASH (clean water, sanitation & hygiene), nutrition, and other poverty-focused development assistance from a faith perspective. His work has focused on providing a solid foundation for US government and private-sector funding of faith- and community-based organizations (FBOs) & (CBOs) as well training their leadership in the US and internationally in writing grant proposals to successfully compete for public- and private-sector support. An advocate for the critical role the faith community plays in foreign assistance, he effectively finds common ground with those wanting to create better lives for people in greatest need. As co-founder and president of Children's AIDS Fund International (formerly Americans for a Sound AIDS/HIV Policy 1986 - 1995), founder and president of the Institute for Youth Development (1995 - 2018), he played a key role in the development and long-term program strategy and implementation of the President's Emergency Plan for AIDS Relief (PEPFAR) prior to its announcement by President George W. Bush in 2003, through its first 20 years of highly effective outcomes, spanning multiple US Government Administrations. Engaged at national, state, district, and local levels in the US and abroad, he worked tirelessly with a range of organizations and foundations seeking to amplify global faith leader voices in advocacy for poverty-focused development assistance and localization as the key to long-term impactful and sustainable programs. He has provided expert testimony before Congress, State legislatures, US AIDS Commissions and multiple international symposia; served on the CDC Director's Advisory Board; represented the US at UNGASS, UNGA, and as part of multiple USG

international delegations. In July 2024, Friends of the Global Fight recognized his longstanding contributions by awarding him a Lifetime Achievement Award in Global Health.



Winnie Byanyima, M.S.

Winnie Byanyima is the Executive Director of UNAIDS and an Under-Secretary-General of the United Nations. A passionate and longstanding champion of social justice issues, Ms Byanyima leads the United Nations' efforts to end AIDS as a public health threat by 2030. Ms Byanyima believes that health care is a human right, and she is the co-chair of the People's Medicines Alliance, advocating for fair access for all to medicines, tests and treatments. Before joining UNAIDS, Ms Byanyima served as the Executive Director of Oxfam International. Previously, she was elected for three terms in the parliament of her country, Uganda. A global leader on gender equality, Ms Byanyima served on Prime Minister Trudeau's Gender Advisory Council during Canada's G7 Presidency and founded the Forum for Women in Democracy, a Ugandan nongovernmental organization. She holds a master of science degree in mechanical engineering from Cranfield University and an undergraduate degree in aeronautical engineering from the University of Manchester. Ms Byanyima is the recipient of four honorary doctorates.



Tom Frieden, M.D.

President and CEO of Resolve to Save Lives, Dr. Tom Frieden is a physician trained in internal medicine, infectious diseases, public health, and epidemiology. He is former director of the US Centers for Disease Control and Prevention and former commissioner of the New York City Health Department.

Dr. Frieden began his public health career in New York City, leading efforts that documented and ended the largest outbreak of multi-drug resistant tuberculosis to occur in the US. He was then assigned to India, on loan from the Centers

for Disease Control and Prevention, where he helped scale up a program for effective tuberculosis diagnosis, treatment, and monitoring that saved millions of lives. Asked to return to New York City to become Mayor Mike Bloomberg's Health Commissioner, he directed efforts to reduce smoking and other leading causes of death that increased life expectancy by 3 years. He helped start Mike Bloomberg's global health philanthropy, particularly the Bloomberg Initiative to Reduce Tobacco Use, which has helped countries implement measures that will prevent more than 35 million deaths. As Director of the US Centers for Disease Control and Prevention, Dr. Frieden oversaw the work that helped end the 2014 West Africa Ebola epidemic.

Dr. Frieden founded Resolve to Save Lives in 2017 and leads the organization's efforts to partner with countries to prevent 100 million deaths from cardiovascular disease and to make the world safer from epidemics. In the organization's first 7 years, these efforts had prevented nearly 8 million deaths.

Dr. Frieden's essays and scientific articles provide insights on a wide range of health problems—and how to address them—in the United States and around the world.



Muhammad Pate, M.D., M.H.S.M.

Muhammad Ali Pate is the Global Director, Health, Nutrition and Population (HNP) Global Practice of the World Bank and the Director of Global Financing Facility for Women, Children and Adolescents (GFF), based in Washington DC. Dr. Pate was until recently the Chief Executive Officer of Big Win Philanthropy, based in the UK, and prior to that held several senior positions, including that of Minister of State for Health in the Federal Republic of Nigeria. He was previously in the World Bank Group where he joined as a Young Professional in 2000 and worked on health issues in several regions including Africa and the East Asia and Pacific.

Dr. Pate is an MD trained in both Internal Medicine and Infectious Diseases, with an MBA from Duke University. Prior to this he studied at the University College London. He also

has a Masters in Health System Management from the London School of Hygiene & Tropical Medicine, UK.



Peter Sands, M.P.A.

Peter Sands became Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria in March 2018.

Sands joined the Global Fund after a distinguished career in banking, most notably as Chief Executive Officer of Standard Chartered PLC from 2006 to 2015. Under his direction, Standard Chartered focused its corporate responsibility initiatives on health issues, including avoidable blindness, AIDS and malaria. During this time, Sands served on the board of the Global Business Coalition on AIDS, Tuberculosis and Malaria and was lead non-executive director on the board of the United Kingdom's Department of Health.

After stepping down from Standard Chartered in 2015, Sands became a research fellow at the Harvard Global Health Institute and the Mossavar-Rahmani Center for Business and Government at Harvard Kennedy School, where he worked on a range of projects at the interface of global health and international finance, publishing papers in the New England Journal of Medicine and The Lancet. In 2015-16, Sands was chair of the U.S. National Academy of Medicine's Commission on a Global Health Risk Framework for the Future, which published the influential report "The Neglected Dimension of Global Security: a Framework to Counter Infectious Disease Threats" in January 2016. In 2016-2017, he chaired the International Working Group on Financing Pandemic Preparedness at the World Bank and from 2017-2023 was also a member of the U.S. National Academy of Science's Forum on Microbial Threats.

Sands has served on numerous boards and commissions, including as a governor of the UK's National Institute for Economic and Social Research, a member of the International Advisory Board of the Monetary Authority of Singapore, a board director of the Institute of International

Finance, and a director of the World Economic Forum. Sands is currently Chair of the Board of Cera, a digital-first home healthcare company based in the UK.

Sands was educated in the UK, Canada and the U.S. He graduated from Brasenose College, Oxford University with a First-Class degree in Politics, Philosophy and Economics. He also received a Master's in Public Administration from Harvard University, where he was a Harkness Fellow.

Preventing Discrimination, Harassment, and Bullying, Expectations for Participants in NASEM Activities

The National Academies of Sciences, Engineering, and Medicine (NASEM) are committed to the principles of diversity, integrity, civility, and respect in all of our activities. We look to you to be a partner in this commitment by helping us to maintain a professional and cordial environment. All forms of discrimination, harassment, and bullying are prohibited in any NASEM activity. This commitment applies to all participants in all settings and locations in which NASEM work and activities are conducted, including committee meetings, workshops, conferences, and other work and social functions where employees, volunteers, sponsors, vendors, or guests are present.

Discrimination is prejudicial treatment of individuals or groups of people based on their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws.

Sexual harassment is unwelcome sexual advances, requests for sexual favors, and other verbal or physical conduct of a sexual nature that creates an intimidating, hostile, or offensive environment.

Other types of harassment include any verbal or physical conduct directed at individuals or groups of people because of their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws, that creates an intimidating, hostile, or offensive environment.

Bullying is unwelcome, aggressive behavior involving the use of influence, threat, intimidation, or coercion to dominate others in the professional environment.

REPORTING AND RESOLUTION

Any violation of this policy should be reported. If you experience or witness discrimination, harassment, or bullying, you are encouraged to make your unease or disapproval known to the individual, if you are comfortable doing so. You are also urged to report any incident by:

- Filing a complaint with the Office of Human Resources at 202-334-3400, or
- Reporting the incident to an employee involved in the activity in which the member or volunteer is participating, who will then file a complaint with the Office of Human Resources.

Complaints should be filed as soon as possible after an incident. To ensure the prompt and thorough investigation of the complaint, the complainant should provide as much information as is possible, such as names, dates, locations, and steps taken. The Office of Human Resources will investigate the alleged violation in consultation with the Office of the General Counsel.

If an investigation results in a finding that an individual has committed a violation, NASEM will take the actions necessary to protect those involved in its activities from any future

discrimination, harassment, or bullying, including in appropriate circumstances the removal of an individual from current NASEM activities and a ban on participation in future activities.

CONFIDENTIALITY

Information contained in a complaint is kept confidential, and information is revealed only on a need-to-know basis. NASEM will not retaliate or tolerate retaliation against anyone who makes a good faith report of discrimination, harassment, or bullying.

Diversity, Equity, and Inclusion Statement and Guiding Principles

We, the National Academies of Sciences, Engineering, and Medicine (the National Academies), value diversity among our staff, members, volunteers, partners, vendors, and audiences. We recognize that talent is broadly distributed in society and that many perspectives enhance the quality of our work and drive innovation and impact.

We pledge to cultivate a workplace culture and climate that promotes inclusion, belonging, accessibility, and anti-racism; upholds equity; and values the participation of all who are engaged in advancing our mission.[1] By embracing the values of diversity, equity, and inclusion in our programs, institutional policies and practices, and products, we will be able to better advise the nation on the most complex issues facing society and the world.

Guiding Principles:

The following diversity, equity, and inclusion principles guide our work at the National Academies:

1. Integrate diverse perspectives and experiences into our programs, institutional policies and practices, and products.
2. Foster a culture of inclusion where all staff, members, and volunteers have full access to participation and feel welcomed, respected, valued, and a sense of belonging.
3. Approach scientific endeavors with a consideration of diversity, equity, and inclusion frameworks.
4. Cultivate mutually beneficial diverse partnerships and collaborations with a variety of communities, including, but not limited to, marginalized and underrepresented communities.

Our institutional strategy for putting these values and principles into practice are outlined in the National Academies DEI Action Plan, a comprehensive five-year plan that charts a path toward achieving our diversity, equity, and inclusion goals. The DEI Action Plan is one of many ways that we commit to systems of accountability and transparency to uphold these principles and allow for continuous learning and improvement.

[1] The National Academies' mission is to provide independent, trustworthy advice and facilitate solutions to complex challenges by mobilizing expertise, practice, and knowledge in science, engineering, and medicine.

